A product for one of the most common childhood cancers
March, 2025
DTU Science Park recently published an article about our collaboration with Y-mAbs Therapeutics. We are both proud and humbled to have worked with them on this extremely important project — bringing a treatment to children battling high-risk neuroblastoma.
A product, that today is available in the U.S. and Chinese markets.
Neuroblastoma is a childhood cancer that arises in the sympathetic nervous system, often near the adrenal glands.
This treatment is a targeted immunotherapy designed for cases where conventional methods like radiation and chemotherapy have failed.
Since 2016, we have collaborated on multiple projects, but this is one we at Bioneer will particularly remember.
With Y-mAbs’ goal of making cancer treatment more effective and gentler for patients in mind, we collaborated on antibody process development, technology development and disease modelling.
A BIG thank you to Y-mAbs for the great collaboration and to DTU Science Park for fostering a thriving professional community.
Read the full article for more details on this groundbreaking product for childhood cancer:
Read more about our services:
